Education
About Us
Working with TipRanks
Follow Us
Innovent Biologics (HK:1801)
:1801
1801 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$28.65 - HK$52.15
Previous CloseN/A
Volume9.75M
Average Volume (3M)12.49M
Market Cap
$63.89B
Enterprise ValueHK$54.07B
Total Cash (Recent Filing)¥7.66B
Total Debt (Recent Filing)¥3.43B
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Mar 26, 2025EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.88
Shares Outstanding1,638,187,500
10 Day Avg. Volume15,372,343
30 Day Avg. Volume12,492,232
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$54.46Price Target Upside39.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Innovent Biologics News
PremiumCompany Announcements
Innovent Biologics Schedules Board Meeting to Approve Annual Results
PremiumCompany Announcements
Innovent Biologics Reports Unusual Market Activity Amid Growth Plans
PremiumCompany Announcements
Innovent Biologics Gains Approval for New Cancer Drug
PremiumCompany Announcements
Innovent Biologics Partners with Roche for ADC Development
PremiumCompany Announcements
Innovent Biologics Unveils Board Composition and Leadership---
Bulls Say, Bears Say
Bulls Say
Product DevelopmentInnovent announced it had received marketing approval from the National Medical Products Administration for its next-generation ROS1 tyrosine kinase inhibitor, DOVBLERON, for the treatment of patients with 2L ROS1+ non-small cell lung cancer.
Strategic PartnershipsInnovent Biologics has out-licensed the global rights of a novel DLL3 ADC to Roche through a blockbuster deal, receiving an upfront payment and potential milestone payments, along with tiered royalties on net sales.
Bears Say
Market CompetitionDLL3-targeted therapy has become increasingly dynamic with significant transactions, highlighting the strategic value of Innovent Biologics' partnerships and assets.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
10.24% Mutual Funds
― Other Institutional Investors
82.65% Public Companies and
Individual Investors
1801 FAQ
What was Innovent Biologics’s price range in the past 12 months?
Innovent Biologics lowest stock price was HK$28.65 and its highest was HK$52.15 in the past 12 months.
What is Innovent Biologics’s market cap?
Innovent Biologics’s market cap is $63.89B.
When is Innovent Biologics’s upcoming earnings report date?
Innovent Biologics’s upcoming earnings report date is Mar 26, 2025 which is in 14 days.
How were Innovent Biologics’s earnings last quarter?
Innovent Biologics released its earnings results on Aug 28, 2024. The company reported -HK$0.258 earnings per share for the quarter, beating the consensus estimate of -HK$0.269 by HK$0.011.
Is Innovent Biologics overvalued?
According to Wall Street analysts Innovent Biologics’s price is currently Undervalued.
Does Innovent Biologics pay dividends?
Innovent Biologics does not currently pay dividends.
What is Innovent Biologics’s EPS estimate?
Innovent Biologics’s EPS estimate is -0.25.
How many shares outstanding does Innovent Biologics have?
Innovent Biologics has 1,638,187,500 shares outstanding.
What happened to Innovent Biologics’s price movement after its last earnings report?
Innovent Biologics reported an EPS of -HK$0.258 in its last earnings report, beating expectations of -HK$0.269. Following the earnings report the stock price went down -0.451%.
Which hedge fund is a major shareholder of Innovent Biologics?
Currently, no hedge funds are holding shares in HK:1801
---
Innovent Biologics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$54.46 (39.63% Upside)
HK$54.46 (39.63% Upside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-0.59%
12-Months-Change
Fundamentals
Return on Equity
-11.09%
Trailing 12-Months
Asset Growth
13.37%
Trailing 12-Months
Company Description
Innovent Biologics
Innovent Biologics, Inc. is an investment company, which engages in the development and manufacture of biopharmaceutical products. Its products include sintilimab (IBI-308), a novel PD-1 antibody; IBI-305, the bevacizumab (Avastin) biosimilar; IBI-301, the rituximab (MabThera/Rituxan) biosimilar; and IBI-303, the (Humira) biosimilar. The company was founded by De Chao Yu, Kevin Chen, and Scott M. Wheelwright on April 28, 2011 and is headquartered in Suzhou, China.
---
1801 Stock 12 Month Forecast
Average Price Target
HK$54.46
▲(39.63% Upside)
Technical Analysis
Ping An Insurance Company of China
―
Sino Biopharmaceutical
―
CSPC Pharmaceutical Group
―
Livzon Pharmaceutical Group
―
Wuxi Biologics (Cayman)
―
Best Analysts Covering 1801
1 Year
1 Year Success Rate
5/7 ratings generated profit
1 Year Average Return
+1.53%
reiterated a buy rating 2 months ago
Copying Jill Wu's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +1.53% per trade.
---